Health Equity & Access to Medicine
Regeneron strives to push the boundaries of science beyond the imaginable. Through innovative access strategies and initiatives that focus on affordability and support, we work to get our medicines to patients in need.
Our performance and progress
Nearly 50
product candidates in clinical development
3M+
exomes sequenced by Regeneron Genetics Center® (RGC) since it was founded in 2013
~$2.8B
in medicines donated through patient assistance programs
Based on 2025 year-end wholesale acquisition cost.
>1.2M
eligible patients received support from our patient support programs
Regeneron patient assistance programs are limited to patients living in the United States and U.S. territories.
~290
patient advocacy and professional societies engaged across 38 diseases to address unmet patient needs
Up to 500 doses
of our Ebola treatment donated to the World Health Organization for exclusive use in low- and lower-middle-income countries
Pipeline innovation for patients
We follow the science to unexpected breakthroughs and diverse areas of study, including understudied diseases. Our pipeline is composed of primarily homegrown therapeutics, powered by our proprietary VelociSuite® technologies and informed by discoveries made in our RGC, one of the largest genetics sequencing efforts in the world.
Inclusive science
We harness the varied experiences of our team to ensure we come up with the best ideas, bring fresh perspectives into our labs and create meaningful collaborations. Throughout the R&D process, we work to facilitate access to our clinical studies and strive for representation of all patient populations.
Explore our current pipeline candidates in a variety of diseases.
Responsible pricing and access
We focus on removing barriers to access to healthcare so people can live their healthiest lives. This includes pricing our medicines with fairness and affordability in mind.
Patient support programs
We help make our products more accessible through our patient support programs. We also provide patient assistance programs designed to provide education and to increase access through insurance eligibility support, patient resources, financial assistance and access to free medicine.
Access to investigational medicines
Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval. Our Managed Access Program gives certain U.S.-based patients who have serious or life-threatening conditions access to a potentially beneficial medicine when no comparable or satisfactory alternative therapy options or clinical trials are available.
Patient assistance foundations
We donate to independent third-party charitable foundations, known as patient assistance foundations, which provide financial assistance to patients who might not otherwise be able to afford their medications.
Patient advocacy
We are deeply committed to understanding the patient community’s challenges and unmet needs. Through our shared, patient-centric approach, we elevate patient voices, improve disease awareness and support equitable access to evidence-based care.
We proudly support a broad range of programs that offer resources to researchers, healthcare providers, patients and their advocates, as well as our local communities. To submit a request for funding, visit our grants portal.
Listening & Learning From the Rare Disease Community
Doing right for those living with unmet needs.
.jpeg)
More than Multiple Myeloma: Illuminating the Power of Advocacy
One person’s journey to learn more inspired her to give back.